No­var­tis' big PD-1 bet turns sour; $350M res­ur­rec­tion sto­ry; Con­tra­cep­tive for men heads to clin­ic; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

The Drug In­for­ma­tion As­so­ci­a­tion’s an­nu­al meet­ing may not have been on every­one’s radar, but the con­ver­sa­tions there could be just as rel­e­vant for the in­dus­try as a whole. And if you missed End­points se­nior ed­i­tor Zach Bren­nan’s se­ries of fire­side chats and pan­els look­ing at the FDA’s next five years, we now have the full videos and tran­scripts avail­able. Check them out be­low.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER